Consumer Medicines Information — Cannabis for Gut & Bowel | MedWest Medical Dispensary
MedWest Medical Dispensary
Where Medicine Meets Wellness · Perth, WA
Consumer Medicines Information
TGA Regulated  ·  Prescription Only
Consumer Medicines Information

Medicinal Cannabis for
Gut & Bowel Conditions

Prepared by MedWest Medical Dispensary to help you understand how THC and CBD may support digestive health, what the research shows, and how to use your medicine safely.

IBS — Irritable Bowel Syndrome IBD — Crohn's & Colitis Visceral Pain Nausea & Motility
10–15%1
of adults worldwide live with IBS — one of the most common functional gut disorders
15–40%2
of IBD patients globally report using cannabis or cannabinoids to manage their symptoms
23
key cannabinoid receptors (CB1 & CB2) are densely expressed throughout the entire gastrointestinal tract

This document contains important information about your medicine. Read it carefully before you start treatment and keep it for future reference. If you have questions, speak with your MedWest pharmacist — we're here to help.

Your Medicine
The two active compounds in your prescription

Medicinal cannabis contains two primary therapeutic compounds — THC and CBD. They work differently and have distinct effects on your gut and digestive system.

T
THC
Tetrahydrocannabinol
The compound that produces a 'high' feeling
  • Reduces cramping and abdominal pain by activating CB1 receptors in gut-lining nerve cells4,5
  • Slows gut motility — helpful for diarrhoea-predominant IBS and urgent, loose stools6
  • Powerfully reduces nausea and vomiting via CB1 receptors in the brainstem5
  • Can stimulate appetite — important if your condition has affected your ability to eat2
  • Reduces the number of daily bowel movements reported in Crohn's disease2
C
CBD
Cannabidiol
Non-intoxicating — won't make you feel 'high'
  • Acts as an anti-inflammatory along the gut lining — relevant for both IBD and IBS7,8
  • Desensitises TRPV1 pain receptors — reducing visceral hypersensitivity and cramping1
  • Helps regulate gut-brain communication, easing the stress-gut-pain cycle5
  • May help protect gut barrier integrity, reducing permeability ("leaky gut")9
  • Reduces anxiety — a key driver of symptom flares in functional bowel disorders10
The Science
How does cannabis support your gut?

Your Body's Own Gut-Control System

Your body has a built-in network called the Endocannabinoid System (ECS). It regulates gut motility (the speed of digestion), pain signals from the bowel, inflammation in the gut wall, and how stress affects your digestive symptoms. CB1 and CB2 receptors — the docking stations for THC and CBD — are found throughout your entire GI tract, from oesophagus to colon. In people with IBS and IBD, this system is often dysregulated. THC and CBD work by interacting with these receptors to restore balance.3,5

⊕Abdominal Pain & Cramping

THC activates CB1 receptors on pain-sensing neurons lining the colon, reducing the intensity of abdominal pain signals sent to the brain. CBD desensitises TRPV1 — a pain-heat receptor overactive in IBS — further dampening cramping.1,4

⊕Diarrhoea & Urgency

THC (particularly dronabinol) has been shown in clinical trials to improve fasting colonic motility and reduce transit speed in diarrhoea-predominant IBS, decreasing urgency and frequency of bowel movements.6

⊕Gut Inflammation (IBD)

In Crohn's disease, cannabis use is associated with improved quality of life, weight gain, reduced disease activity, and lower CDAI scores. Cannabinoids may help by modulating inflammatory pathways via CB2 receptors on immune cells in the gut.2,7

⊕Nausea & Appetite

THC is one of the most well-evidenced anti-nausea agents in medicine. CB1 activation in the brainstem's dorsal vagal complex inhibits the emetic (vomiting) reflex and settles nausea associated with gut conditions and flares.5

⊕Stress-Triggered Flares

Stress activates the HPA axis, which in turn dysregulates CB1 in colon-connected nerve cells and worsens visceral pain. CBD helps reduce HPA stress activity centrally, breaking the stress–gut–pain cycle common in IBS.5,10

⊕Gut Barrier & Permeability

CBD and its close compound palmitoylethanolamide (PEA) have been shown to reduce gut hyperpermeability in human tissue models — a key mechanism in IBD. This may help reduce the chronic low-grade inflammation underpinning symptoms.9

Using Your Medicine
Dosing guidance — start low, go slow

Everyone's body is different. Your prescriber will tailor your dose, but the following ranges reflect what has been used in clinical research and Australian practice. Always begin at the lowest dose and increase only if needed after at least one week.

THC — Gut Applications
New to cannabis2.5–5 mg
Some experience5–10 mg
Frequency1–2× daily
Best timingWith or after food
CBD — Gut Applications
Starting dose15–25 mg
Therapeutic range25–75 mg
Frequency1–3× daily
Best timingWith a fatty meal
A note on formulations: Oils and capsules taken orally are absorbed through the gut and provide a slower, longer-lasting effect (onset 60–120 min, duration 4–8 hrs) — often preferred for chronic gut conditions. Vaporised flower acts faster (onset 10–20 min) and may be better for acute flares. Your MedWest pharmacist can advise on the most appropriate formulation for your situation.
Treatment Journey
What a typical treatment period looks like
Week 1–2 — Starting Out
Low dose, observing effects
Begin at the lowest dose. You may notice some early relief from nausea, cramping, or urgency. Some patients feel mild drowsiness or a gentle 'high' — this often reduces as your body adjusts. Keep a simple symptom diary to track changes.
Week 2–4 — Titration
Finding your therapeutic dose
If symptoms are not adequately controlled, your dose can be carefully increased. Most gut-related benefits are seen in the 5–10 mg THC or 25–50 mg CBD range, though individual responses vary. Never increase both compounds simultaneously.
Month 1–3 — Maintenance
Stable symptom management
Many patients find a consistent dose that manages their symptoms well. Regular check-ins with your prescriber allow for review and adjustments. Some patients cycle their medication — taking planned breaks — to maintain effectiveness.
Ongoing
Monitoring and review
Your MedWest pharmacist tracks your treatment. If a flare occurs, a temporary dose increase may be appropriate. Medicinal cannabis works best alongside dietary management, stress reduction, and regular review with your gastroenterologist or GP.
Important Safety Information
Please read carefully

⚠ Safety Considerations

Medicinal cannabis affects everyone differently. THC may cause temporary dizziness, dry mouth, increased appetite, or mild cognitive effects — especially at higher doses or when starting treatment. Do not drive or operate machinery until you know how your medicine affects you.

High-dose or very frequent THC use over a long period can, rarely, be associated with Cannabinoid Hyperemesis Syndrome (CHS) — a paradoxical condition involving cyclical nausea and vomiting. If you develop worsening nausea or vomiting with regular use, contact your MedWest pharmacist immediately.

Medicinal cannabis is not recommended for people under 25, during pregnancy or breastfeeding, or for those with a personal or family history of psychosis or schizophrenia. It can interact with some medications — always tell your pharmacist about all medicines you take.

Current evidence for cannabinoids in gut conditions is most established for Crohn's disease symptom relief. Evidence for ulcerative colitis is less clear, and clinical trials are ongoing. Your prescriber will have assessed whether this treatment is appropriate for your specific diagnosis.

Questions to Ask Your MedWest Pharmacist
  • What ratio of THC to CBD is right for my gut condition specifically?
  • Will this interact with my current IBD or IBS medications?
  • Should I take my cannabis before or after meals for gut conditions?
  • How do I know if my dose needs adjusting after a flare?
  • Can I drive to work if I take a low-dose CBD product only?
  • What should I do if my nausea or bowel symptoms get worse on this medicine?
Contact MedWest
📞 (08) 6256 1512
Shop 17, 478 Wanneroo Road, Westminster WA 6061

Where This Information Comes From

The information in this guide is based on peer-reviewed research. References are provided for transparency using Vancouver style — you don't need to read them, but they're here if you'd like to learn more.

  1. Brierley SM, Greenwood-Van Meerveld B, Sarnelli G, Sharkey KA, Storr M, Tack J. Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome. Nat Rev Gastroenterol Hepatol. 2023;20(1):5–25. doi: 10.1038/s41575-022-00682-y
  2. Odkhuu E, Kim TH, Lee CH. The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature. Biomedicines. 2023;11(4):1041. PMC: PMC10101654
  3. Sharkey KA, Wiley JW. The Role of the Endocannabinoid System in the Brain–Gut Axis. Gastroenterology. 2016;151(2):252–266. doi: 10.1053/j.gastro.2016.04.015
  4. Brugnatelli V, Turco F, Freo U, Zanette G. Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment. Front Neurosci. 2020;14:371. PMC: PMC7186328
  5. Camilleri M. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects and potential therapeutics in humans. United European Gastroenterol J. 2018;6(1):5–13. PMC: PMC6150799
  6. Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141(5):1638–1647. PMC: PMC3775711
  7. Maccioni L, Gras-Miralles B, Bhattarai Y, et al. Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022;11(20):6095. PMC: PMC9599014
  8. Engel MA, Neurath MF. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol. 2017;11(4):329–337. doi: 10.1080/17474124.2017.1292851
  9. Couch DG, Cook H, Ortori C, et al. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo — A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019;25(6):1006–1018. doi: 10.1093/ibd/izz017
  10. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016;1(1):154–165. PMC: PMC5576607

MedWest Medical Dispensary  ·  Shop 17, 478 Wanneroo Road, Westminster WA 6061  ·  (08) 6256 1512

This Consumer Medicines Information guide is for educational purposes and does not replace personalised advice from your pharmacist or doctor. Medicinal cannabis in Australia is a Schedule 8 controlled medicine regulated by the TGA, accessed via the Special Access Scheme (SAS) or Authorised Prescriber (AP) Scheme. Your suitability for treatment is assessed individually. If you have any questions about your medicine — big or small — please ask your MedWest pharmacist.

© 2026 MedWest Medical Dispensary Pty Ltd · ABN 80 428 729 037 · MedWest acknowledges the Traditional Owners of the Whadjuk Noongar land where we work and live.